1. Adelaide Research & Scholarship

Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 10 (Search time: 0.004 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2003Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controlsHaynes, D.; Barg, E.; Crotti, T.; Holding, C.; Weedon, H.; Atkins, G.; Zannettino, A.; Ahern, M.; Coleman, M.; Roberts-Thomson, P.; Kraan, M.; Tak, P.; Smith, M.
2020HOPX regulates bone marrow-derived mesenchymal stromal cell fate determination via suppression of adipogenic gene pathwaysHng, C.H.; Camp, E.; Anderson, P.; Breen, J.; Zannettino, A.; Gronthos, S.
2015Bone marrow recovery by morphometry during induction chemotherapy for acute lymphoblastic leukemia in childrenNguyen, T.; Melville, A.; Nath, S.; Story, C.; Howell, S.; Sutton, R.; Zannettino, A.; Revesz, T.; Bandapalli, O.
2008Multipotential human adipose-derived stromal stem cells exhibit a perivascular phenotype in vitro and in vivoZannettino, A.; Paton, S.; Arthur, A.; Khor, F.; Itescu, S.; Gimble, J.; Gronthos, S.
2010Comparative assessment of the osteoconductive properties of different biomaterials in vivo seeded with human or ovine mesenchymal stem/stromal cellsZannettino, A.; Paton, S.; Itescu, S.; Gronthos, S.
2003A novel CD44 antibody identifies an epitope that is aberrantly expressed on acute lymphoblastic leukaemia cellsBendall, L.; James, A.; Zannettino, A.; Simmons, P.; Gottlieb, D.; Bradstock, K.
2005Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cellsKortesidis, A.; Zannettino, A.; Isenmann, S.; Shi, S.; Lapidot, T.; Gronthos, S.
2010Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: A mechanism for improved insulin sensitivity in Type 2 diabetic CML patients?Fitter, S.; Vandyke, K.; Schultz, C.; White, D.; Hughes, T.; Zannettino, A.
2007Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activityWhite, D.; Saunders, V.; Dang, P.; Engler, J.; Venables, A.; Zrim, S.; Zannettino, A.; Lynch, K.; Manley, P.; Hughes, T.
2013Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: Evidence for site-specific skeletal effectsVandyke, K.; Fitter, S.; Drew, J.; Fukumoto, S.; Schultz, C.; Sims, N.; Yeung, D.; Hughes, T.; Zannettino, A.

Discover